[Control of fertility by medroxyprogesterone acetate].
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002582:Cervix Mucus / Q000187:drug effects; D004341:Drug Evaluation; D004717:Endometrium / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005640:Follicle Stimulating Hormone / Q000652:urine; D006801:Humans; D007986:Luteinizing Hormone / Q000652:urine; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000494:pharmacology*; D008599:Menstruation Disturbances / Q000139:chemically induced; D008875:Middle Aged; D010053:Ovary / Q000187:drug effects; D011276:Pregnanediol / Q000652:urine
D015068:17-Ketosteroids; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone; D011276:Pregnanediol
Control de la fertilidad mediante el empleo de acetato de medroxiprogesterona (MPA)